Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia

NCT01615809 is registered in ClinicalTrials.gov with Fundació Sant Joan de Déu as lead sponsor.

NCT NCT01615809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01615809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia
Lead sponsor
Fundació Sant Joan de Déu
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
July 31, 2013
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

invasive pulmonary aspergillosis, lymphoblastic leukaemia, lymphoblastic leukemia, myeloblastic leukaemia, myeloblastic leukemia